Login to Your Account



Other News To Note


Thursday, October 31, 2013
• Opthea Pty Ltd., of Melbourne, Australia, a subsidiary of Circadian Technologies Ltd., inked an agreement with manufacturing and technology firm DSM Pharmaceutical Products covering process development and cGMP manufacturing for Opthea’s lead molecule, a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel formation and are involved in the progression of eye diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription